Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Authors:
- Ben DavidsonBDBen Davidson
- 1 June 2010
- journal article
- Published by Elsevier in Human Pathology
- Vol. 41 (6) , 794-804
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Biological Characteristics of Cancers Involving the Serosal CavitiesCritical Reviews™ in Oncogenesis, 2007
- PTEN function in normal and neoplastic growthCancer Letters, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Treatment goals in ovarian cancerInternational Journal of Gynecological Cancer, 2005
- The activation of Akt/PKB signaling pathway and cell survivalJournal of Cellular and Molecular Medicine, 2005
- Apoptotic Pathways and Therapy Resistance in Human Malignancies2005
- Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting2005
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- The phosphatidylinositol 3-Kinase–AKT pathway in human cancerNature Reviews Cancer, 2002
- The Prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian CancerGynecologic Oncology, 1995